FY2024 Earnings Forecast for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Issued By HC Wainwright

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a research note issued on Wednesday, April 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($2.79) per share for the year, up from their previous estimate of ($2.80). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.87 EPS.

DAWN has been the subject of a number of other reports. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $14.92 on Friday. The stock has a market cap of $1.30 billion, a PE ratio of -6.27 and a beta of -1.48. The stock has a 50-day moving average of $15.22 and a 200-day moving average of $13.83. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Insider Activity at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 7,615 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the completion of the transaction, the chief executive officer now directly owns 721,813 shares in the company, valued at approximately $11,007,648.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the transaction, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 7,615 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the transaction, the chief executive officer now directly owns 721,813 shares of the company’s stock, valued at approximately $11,007,648.25. The disclosure for this sale can be found here. In the last three months, insiders sold 55,781 shares of company stock worth $883,160. 8.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. SG Americas Securities LLC boosted its holdings in shares of Day One Biopharmaceuticals by 58.7% in the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after buying an additional 13,683 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Day One Biopharmaceuticals by 22.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after buying an additional 8,522 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Day One Biopharmaceuticals by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock valued at $677,000 after buying an additional 27,598 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 89.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after buying an additional 25,414 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.